All In Biotech

Drug Trial Radar · NCT00490360

Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head

Last checked: Nov 19, 2026Latest source record: Jun 22, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,007

Actual

Start

Oct 2001

Primary completion

Not stated

Study completion May 2007

Sponsor

Lead sponsor
University of ZurichAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head.

Conditions

  • Cancer of the Pancreatic Head

Interventions

  • Gemcitabine / CisplatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Resectability rate > 70% after restagingTime frame: 2007

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Zurich, Department of Surgery

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.